Furthermore, we reveal the pro-invasive consequences of targeted inhibition of FASN and ERα signalling in ERα-positive breast cancers and we provide evidence for the therapeutic potential of caveolin-1 in this specific context. This evidence concerns the gene ESR1 and breast cancer.